Sensitive enough to measure high affinity and covalent binding events, the Pioneer systems also uses a unique OneStep® gradient injection technology to facilitate fragment screening.
| BENGALURU, KA, India and SAN JOSE, Calif., May 20, 2019 /PRNewswire/ -- Jubilant Biosys, a wholly owned subsidiary of Jubilant Life Sciences, announced today that it has recently added advanced Pioneer FE system to their platform of drug discovery solutions available to customers. The Pioneer FE system from ForteBio, Inc., the Biologics Business Unit of Molecular Devices, represents the next generation SPR instrumentation for label-free characterization of biomolecules. Sensitive enough to measure high affinity and covalent binding events, the Pioneer systems also uses a unique OneStep® gradient injection technology to facilitate fragment screening. Pioneer systems with OneStep technology can analyze up to 768 fragments in 24 hours, obtaining kinetics during the primary screen and eliminating the need for additional screens.
The Pioneer system is the first unit placed in India, and part of Jubilant’s continuing investment in new technologies supporting their innovator customer needs. Said Marcel Velterop, President of Jubilant Biosys, “The addition of the Pioneer SPR system will significantly upgrade and speed up our small molecule hit-finding engine for novel target classes.” Greg Milosevich, President of Molecular Devices, commented, “We are pleased to have Jubilant adopt the Pioneer platform and look forward to supporting them and their customers’ goals in fast-tracking small molecule drug discovery programs.” About Jubilant Biosys Limited About Molecular Devices, LLC Contact for Molecular Devices Craig Tin Contact for Jubilant Biosys Drishti Asthana
SOURCE ForteBio |
View original content to download multimedia:
